Home ••• Newswires by Industry • Countries • U.S. States • World Media Directory

Lung Cancer News ••• Topics • Countries • U.S. States

Non-Small Cell Lung Cancer (NSCLC) News Monitoring

Get by Email • RSS

Published on May 31, 2025

Molecularly Guided Chemotherapy Boosts Survival in Early NSCLC

The interim analysis of the international, multicenter, prospective, randomized AIM-HIGH trial (NCT01817192) revealed a substantial improvement in disease-free survival (DFS) at 24 months for patients with stage IA to IIA nonsquamous non–small cell lung …

Source: Targeted Oncology - Pending
Published on Jun 1, 2025

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

Regeneron's PD-1 inhibitor Libtayo could find wider use for a form of skin cancer known as cutaneous squamous cell carcinoma after showing efficacy in a pivotal trial as adjuvant therapy for patients who have had surgery to remove their tumour. New …

Source: pharmaphorum - Neutral
Published on Jun 1, 2025

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated patients. That is thanks to new data from the ASCENT- …

Source: pharmaphorum - Neutral
Published on Jun 1, 2025

Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism

The addition of amivantamab-vmjw (Rybrevant) to chemotherapy demonstrated improved efficacy and progression-free survival outcomes compared with chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer (NSCLC) following disease …

Source: OncLive - Pending
Published on 05:57 GMT

Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback

Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation’s pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Akeso’s shares fell 11.6 per …

Source: South China Morning Post - Indeterminate
Published on May 31, 2025

Adjuvant Chemotherapy Improves DFS in Molecularly Higher-Risk NSCLC

Adjuvant chemotherapy yielded a disease-free survival (DFS) benefit vs observation in patients with stage IA to IIA nonsquamous non–small cell lung cancer (NSCLC) who were identified as high or intermediate risk by the 14-gene RiskReveal prognostic assay, …

Source: OncLive - Pending
Published on May 31, 2025

Ivonescimab Sheds Light on NSCLC Immuno-Angiogenesis

The landscape of non-small cell lung cancer (NSCLC) treatment has undergone a radical transformation in recent years, driven by advances that integrate immunotherapy with the manipulation of angiogenic pathways. Central to this evolving paradigm is …

Source: Bioengineer.org - Pending
Published on Jun 1, 2025

Brain Metastases Re-Resection: Outcomes Revealed

In the evolving landscape of neuro-oncology, brain metastases pose a formidable challenge, often impacting patient survival and quality of life. Recent advances in microsurgical techniques and adjuvant therapies have improved outcomes for many, yet …

Source: Bioengineer.org - Pending
Published on May 31, 2025

Enhancing NSCLC Brain Metastasis Treatment With MR-Guided Ultrasound: Manmeet Ahluwalia, MD, MBA, FASCO

Combining magnetic resonance (MR)-guided focused ultrasound with microbubbles and immune checkpoint inhibitors (ICIs) could transform non-small cell lung cancer (NSCLC) treatment by reducing radiation side effects and increasing intracranial response rates …

Source: The American Journal of Managed Care - Neutral
Published on May 31, 2025

Dr Goldman on the Efficacy of Telisotuzumab Vedotin in Advanced NSCLC With c-MET Overexpression

“The primary end point of LUMINOSITY was the objective response rate in the c-MET–high group. It was 35%, so it was meaningfully superior to 2 other FDA-approved agents in the second-line setting.” Jonathan W. Goldman, MD, a professor of medicine in the …

Source: OncLive - Pending
Published on May 31, 2025

Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

"This [is] an analysis of the progression-free survival [stratified] by molecular aberration, which represents the mechanism of resistance post-osimertinib [in] all patients who were enrolled in the MARIPOSA-2 study. The data [show] is that …

Source: OncLive - Pending
Published on Jun 1, 2025

A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising

Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to …

Source: BioPharma Dive - Pending
Published on May 31, 2025

Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI

Ivonescimab in combination with platinum-doublet chemotherapy met the coprimary end point of the phase 3 HARMONi trial (NCT06396065), demonstrating a significant improvement in progression-free survival (PFS) compared with placebo plus platinum-doublet …

Source: OncLive - Pending
Published on Jun 1, 2025

Beyond Awareness: Modeling Shared Decision-Making in Patient Communications

When Coretta learned she had stage 4 non-small cell lung cancer, she was blindsided. She didn’t fit the profile. She didn’t see it coming. And she didn’t know what to do next. It’s a common experience in serious diagnoses—patients feel not just fear but …

Source: Pharmaceutical Commerce - Pending
Published on Jun 1, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical ...

PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical …

Source: WFMZ - Pennsylvania - Neutral
Published on May 31, 2025

Tumor-Microenvironment Crosstalk Drives NSCLC Progression, Therapy Response

The landscape of non-small-cell lung cancer (NSCLC) treatment is transforming at an unprecedented pace, shaped profoundly by the integration of targeted therapies and immunotherapeutic approaches. Though these advances have significantly improved patient …

Source: Bioengineer.org - Pending
Published on May 30, 2025

Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC

The addition of ivonescimab (SMT112) to chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) outcomes vs chemotherapy alone in patients with EGFR-mutant locally advanced or …

Source: Cancer Network - New Jersey - Pending
Published on Jun 1, 2025

ASCO: AstraZeneca looks to bring immunotherapy to early-stage stomach cancer with Imfinzi

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen of FLOT both before and after surgery lowered the risk of …

Source: Fierce Pharma - Neutral
Published on May 30, 2025

Proactive Dermatologic Care Reduces Symptom Severity and Boosts Quality of Life in NSCLC

Enhanced dermatologic management (COCOON DM) in combination with amivantamab (Rybrevant, Janssen Biotech, Inc.) plus lazertinib (Lazcluze, Janssen Biotech, Inc.) significantly reduced the incidence of grade 2 or greater dermatologic adverse events (AEs) …

Source: Pharmacy Times - Neutral

30 days 02:23:07

Featured Releases

Got News to Share? · Submit · See All

Published on June 2, 2025 - 00:00 GMT

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on May 31, 2025 - 18:46 GMT

Quitting tobacco? Here are five facts to help you

May 31 is World No Tobacco Day. If you’ve tried to stop using tobacco before and then started again, don’t be discouraged! You can use this observance to start creating a plan for how to stop, which will greatly increase your chances of quitting for good. …

Distribution channels:

Published on May 31, 2025 - 12:04 GMT

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell ...

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on May 31, 2025 - 12:00 GMT

Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025

Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated incidence and mortality in a high-risk population Data …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on May 31, 2025 - 12:00 GMT

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …

Distribution channels: Companies, Culture, Society & Lifestyle ...
Published on May 31, 2025 - 12:00 GMT

ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025

– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …

Distribution channels: Technology ...
Published on May 30, 2025 - 11:39 GMT

In-Depth Analysis Of The Global Sarcoidosis Market: Key Drivers, Trends, Growth Opportunities, And Forecast 2025-2034

The Business Research Company’s Sarcoidosis Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, May 30, 2025 /⁨EINPresswire.com⁩/ -- What Is The Forecasted Growth Of The Sarcoidosis …

Distribution channels: Business & Economy, Chemical Industry ...
Published on May 30, 2025 - 12:30 GMT

Novel Drug Delivery System Market to Reach $67.3Bn by 2031, Growing at 21.2% CAGR | DataM Intelligence

Novel Drug Delivery System Market to reach $67.3B by 2031, growing at 21.2% CAGR due to nanotech, biologics, and patient-driven drug delivery solutions. NEW YORK, NY, UNITED STATES, May 30, 2025 /⁨EINPresswire.com⁩/ -- Market Overview The Novel …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Got news to share? Submit it now.

Load more lung cancer news or search news using your own keywords. There are 818,190,838 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Lung Cancer News by Country

Lung Cancer News by U.S. State

Lung Cancer News Topics

Online News Publications

World News Report

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter

Create RSS Feed

NewsPlugin for WordPress

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire

Events

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 05/18/2025

World Media Directory

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All

Published on June 2, 2025 - 06:51 GMT

Narconon Arrowhead Hosts Celebration for Graduate's 25 Years of Sobriety

CANADIAN, OK, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- The Narconon Arrowhead Drug and Alcohol Rehabilitation Program recently hosted a special celebration as Bobby Newman, a program graduate, marked 25 years of sobriety. Newman, who …

Distribution channels: Culture, Society & Lifestyle, Education ...
Published on June 1, 2025 - 23:16 GMT

Luis M. Gallardo Launches the Meta Pets Method, A Playful Path to Transformation for Therapists, Coaches, and Educators

A Card-Based System for Self-Inquiry, Healing, and Awakening in Education, Coaching, and Therapy. MIAMI, FL, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- Author, hypnotherapist, and global well-being advocate Luis Miguel Gallardo announces …

Distribution channels: Book Publishing Industry, Business & Economy ...
Published on June 1, 2025 - 23:00 GMT

Impelsys Strengthens AI Transformation Strategy with AlgoShack Partnership

NEW YORK, NY, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Impelsys, a global leader in technology solutions, is pleased to announce its strategic partnership with AlgoShack, a company that offers algoQA—a unified platform for end-to-end …

Distribution channels: Book Publishing Industry, Education ...
Published on June 2, 2025 - 05:00 GMT

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short ...

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) ( …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 05:00 GMT

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 05:00 GMT

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 05:00 GMT

Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques ...

Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé, en croissance rapide, pour la …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 02:29 GMT

Colorado public health officials release additional locations for potential measles exposures

The DEN airport case has resulted in three additional confirmed cases of measles Denver (June 1, 2025) — The Colorado Department of Public Health and Environment and El Paso County Public Health have confirmed measles in two adult unvaccinated El Paso …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 2, 2025 - 02:06 GMT

Volunteers support the NHS for 6 million hours this year

Tens of thousands of people have volunteered to help the NHS over the last year, according to new figures. From people in their late teens to those in their late eights volunteers have helped with tasks such as directing loved ones around hospitals, …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 2, 2025 - 00:00 GMT

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on June 1, 2025 - 23:30 GMT

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“ …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 1, 2025 - 23:26 GMT

TORRAS Personal Cooling with Coolify Series: A Tech-Driven Solution for Comfort, Wellness, and Women's Health

LOS ANGELES, June 01, 2025 (GLOBE NEWSWIRE) -- As global temperatures continue to rise and daily comfort becomes a growing concern, TORRAS is making waves with its innovative Coolify series—a wearable air conditioner engineered to deliver rapid, personal …

Distribution channels:
Published on June 1, 2025 - 23:00 GMT

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in ...

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on June 1, 2025 - 05:21 GMT

Smile Scarsdale Family Dental Celebrates One Year of Smiles as Trusted Family Dentist in Scarsdale

SCARSDALE, NY, UNITED STATES, May 31, 2025 /⁨EINPresswire.com⁩/ -- Smile Scarsdale Family Dental is proud to celebrate its one-year anniversary of delivering exceptional family dental care to the Scarsdale community and surrounding areas. Since …

Distribution channels: Culture, Society & Lifestyle, Emergency Services ...
Published on June 1, 2025 - 17:12 GMT

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/...

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 1, 2025 - 14:45 GMT

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated ...

Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 1, 2025 - 14:00 GMT

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 ...

- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
Published on June 1, 2025 - 00:41 GMT

Planet TV Studios Presents New Frontiers Episode 'Highlighting Emerging Technologies' Featuring Athena Clinic & Dr. ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON,, FL, UNITED STATES, May 31, 2025 …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on June 1, 2025 - 00:35 GMT

Planet TV Studios Presents New Frontiers: Innovators Shaping Tomorrow. The content in the episode is a Planet TV Studios ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON, FL, UNITED STATES, May 31, 2025 …

Distribution channels: Companies, Culture, Society & Lifestyle ...
Published on June 1, 2025 - 00:33 GMT

'New Frontiers' Presents 4 Companies Revolutionizing: Brian Cancer Therapies, Robotic Surgery, Sustainable Solutions & ...

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. New Frontiers: "Highlighting Emerging Technologies" will air May 31st 2025 on Bloomberg Television at 5:00 pm ET. BOCA RATON, FL, UNITED STATES, May 31, 2025 …

Distribution channels: Companies, Culture, Society & Lifestyle ...